Latest Articles

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Lp(a) as ASCVD risk factor

Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

LLTs Exposure Time and Major Vascular Risk Reduction

New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua^®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Galimberti F, et al. Poster presented at the 91st European Atherosclerosis Society congress (EAS) 2023.

LDL-C The Only Causal Risk Factor for ASCVD

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia